Patient diagnosed with chronic erectile dysfunction refractory to PDE 5 Inhibitor therapy reports improvement in function after hyperbaric oxygen therapy
Abstract
Erectile dysfunction (ED), defined as the inability to achieve or sustain an erection firm enough for sexual intercourse, is common in men older than 50 years of age whose medical history includes diabetes mellitus. This case report describes a male patient treated with hyperbaric oxygen (HBO₂) therapy as part of a comprehensive wound treatment plan for an open right foot wound. The patient's medical history included Type 1 diabetes mellitus and chronic ED refractory to previous trials of phosphodiesterase type 5 inhibitors. The patient completed a total of 60 HBO₂ treatments over a 15-week period. He reported an improvement in his ED symptoms after the first 20 hyperbaric treatments, with morning tumescence being the first sign of a change. Patient continued to report morning tumescence 24 weeks after final HBO₂ treatment.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Protective effects of tadalafil and N-acetyl cysteine therapy on cisplatin-induced testicular toxicity
- The Use of Generative AI for Scientific Literature Searches for Systematic Reviews: ChatGPT and Microsoft Bing AI Performance Evaluation
- Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons
- Ozone-modified properties of pumpkin seed oil as anti-H. pylori, anticancer, anti-diabetic and anti-obesity agent
- Effectiveness of Low-Intensity Extracorporeal Shock Wave Therapy in Erectile Dysfunction: An Analysis of Sexual Function and Penile Hardness at Erection: An Umbrella Review
- Molecular Docking of Silymarin as a Ligand for Aromatase Enzyme and HIV-1 Reverse Transcriptase Using Molegro Virtual Docker
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.